March 29th 2023
Adding avelumab to VEGFR inhibitor axitinib may prolong survival and improve outcomes among patients with recurrent/metastatic adenoid cystic carcinoma.
Questions Remain About the Role of Transoral Surgery for Oropharyngeal CancerAugust 19th 2019
Researchers compared the swallowing-related quality-of-life scores of patients with oropharyngeal squamous cell carcinoma who received radiotherapy and patients who received transoral robotic surgery with neck dissection.
Should Surveillance Schedules Apply to HPV-Associated Oropharyngeal Squamous Cell Carcinomas?August 16th 2019
A new study looked at what methods were used to detect recurrences of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma to see if surveillance guidelines recommended by the National Comprehensive Cancer Center were effective.
Durvalumab Shows Promise in Advanced Head and Neck CancerFebruary 20th 2018
A phase II trial found that the immune checkpoint inhibitor durvalumab has promising clinical activity and is well tolerated both as monotherapy and in combination with tremelimumab in patients with heavily pretreated recurrent or metastatic head and neck cancer, whose tumors are PD-L1 low or negative.
Adding Nivolumab to Standard First-Line Therapy Feasible in Advanced Head and Neck CancerFebruary 20th 2018
An early phase trial found that it is feasible to combine nivolumab immunotherapy with radiation therapy and chemotherapy in patients with newly diagnosed local-regionally advanced head and neck cancers.
Reduced RT Feasible in Chemo-Sensitive HPV-Associated Head and Neck CancerFebruary 19th 2018
Patients with human papillomavirus–associated head and neck cancers who respond well to induction therapy can receive substantially lower doses of radiation and still achieve good safety and efficacy outcomes, according to a new phase II trial.
Emergence of a Novel Staging System for Oropharyngeal Squamous Cell Carcinoma Based on HPV StatusDecember 15th 2017
The staging of oropharyngeal squamous cell carcinoma has undergone key changes in the eighth edition of the American Joint Committee on Cancer Staging Manual, set to take effect January 1, 2018. We describe the revised staging parameters and the rationale in support of the changes.
Pretreatment Cognitive Impairment Is Common in Patients With Head and Neck CancerDecember 1st 2017
Results from a study of patients with newly diagnosed head and neck cancer indicate that cognitive screening should be incorporated into pretreatment assessment for patients in order to improve outcomes.